单细胞转录基因组测序提供了对耐火DLBCL患者多重化疗耐药性的洞察力:一个病例报告
Kewei Zhao1, Qiuhui Li1, Pengye Li1
1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in immunology
|March 27, 2024
概括
单细胞测序揭示了复发性扩散大B细胞淋巴瘤 (DLBCL) 的瘤异质性和免疫抑制. 这种方法有助于确定耐药DLBCL的潜在治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 复发性和耐火性扩散性大B细胞淋巴瘤 (DLBCL) 是一个严重的临床挑战,预后不佳.
- 了解内异质性和免疫微环境对于开发有效疗法至关重要.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


